Literature DB >> 10594569

Oligo-monoclonal immunoglobulins frequently develop during concurrent cytomegalovirus (CMV) and Epstein-Barr virus (EBV) infections in patients after renal transplantation.

E Drouet1, C Chapuis-Cellier, S Bosshard, C Verniol, A Niveleau, J L Touraine, J L Garnier.   

Abstract

In the present study we report that the appearance of oligo-monoclonal immunoglobulins (oligoM-Igs) in the sera of transplanted individuals is concurrent with the detection of coincident active CMV infection and EBV replication. Eighty-four renal allograft patients were monitored with respect to CMV isolation, to CMV conventional serology and humoral response against the EBV trans-activator ZEBRA (an immediate-early antigen also called BZLF1). Titration of anti-ZEBRA antibodies (IgG and IgM) and amount of EBV DNA in serum were evaluated. Using the combination of four techniques (agarose gel electrophoresis, analytical isoelectric focusing, high resolution immunoelectrophoresis, immunofixation electrophoresis), oligoM-Igs were found in 25% of patients after allografting and significantly associated with rejection episodes (P < 0.001). Twenty out of 23 (86%) concurrent CMV/EBV infections were associated with serum oligoM-Igs (P < 0.001). One can thus reasonably assume that a sustained EBV replication following iatrogenic immunosuppression can promote the immunoglobulin heavy chain expression in EBV-infected B lymphocytes. The proliferation of immunoglobulin-secreting clones might occur after active CMV infection, through a transient over-immunosuppression or via immune subversion.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10594569      PMCID: PMC1905451          DOI: 10.1046/j.1365-2249.1999.01084.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  40 in total

1.  Monoclonal and multiclonal gammopathies after renal transplantation.

Authors:  C K Stanko; J R Jeffery; D N Rush
Journal:  Transplant Proc       Date:  1989-04       Impact factor: 1.066

2.  Detection of cytomegaloviremia using monoclonal antibodies.

Authors:  M C Mazeron; R Colimon; A Roseto; Y Perol
Journal:  Dev Biol Stand       Date:  1984

3.  Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease.

Authors:  R Mañez; M C Breinig; P Linden; J Wilson; J Torre-Cisneros; S Kusne; S Dummer; M Ho
Journal:  J Infect Dis       Date:  1997-12       Impact factor: 5.226

4.  Epstein-Barr virus associated lymphoproliferative diseases (B cell lymphoma) after transplantation.

Authors:  J L Garnier; F Berger; H Betuel; M Vuillaume; C Chapuis-Cellier; N Blanc; J L Faure; J M Dubernard; G Lenoir; J L Touraine
Journal:  Nephrol Dial Transplant       Date:  1989       Impact factor: 5.992

5.  Quantitative oropharyngeal Epstein-Barr virus shedding in renal and cardiac transplant recipients: relationship to immunosuppressive therapy, serologic responses, and the risk of posttransplant lymphoproliferative disorder.

Authors:  J K Preiksaitis; F Diaz-Mitoma; F Mirzayans; S Roberts; D L Tyrrell
Journal:  J Infect Dis       Date:  1992-11       Impact factor: 5.226

6.  Monoclonal gammapathies in patients undergoing immunosuppressive treatment after renal transplantation.

Authors:  J Radl; R M Valentijn; J J Haaijman; L C Paul
Journal:  Clin Immunol Immunopathol       Date:  1985-10

7.  Quantitative evaluation of Epstein-Barr-virus-infected mononuclear peripheral blood leukocytes in infectious mononucleosis.

Authors:  G Rocchi; A Felici; G Ragona; A Heinz
Journal:  N Engl J Med       Date:  1977-01-20       Impact factor: 91.245

8.  Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection.

Authors:  M Ho; G Miller; R W Atchison; M K Breinig; J S Dummer; W Andiman; T E Starzl; R Eastman; B P Griffith; R L Hardesty
Journal:  J Infect Dis       Date:  1985-11       Impact factor: 5.226

9.  Epstein-Barr virus BZLF1 trans-activator specifically binds to a consensus AP-1 site and is related to c-fos.

Authors:  P J Farrell; D T Rowe; C M Rooney; T Kouzarides
Journal:  EMBO J       Date:  1989-01       Impact factor: 11.598

10.  A transcription factor with homology to the AP-1 family links RNA transcription and DNA replication in the lytic cycle of Epstein-Barr virus.

Authors:  A Schepers; D Pich; W Hammerschmidt
Journal:  EMBO J       Date:  1993-10       Impact factor: 11.598

View more
  5 in total

1.  Signature biochemical properties of broadly cross-reactive HIV-1 neutralizing antibodies in human plasma.

Authors:  Mohammad M Sajadi; George K Lewis; Michael S Seaman; Yongjun Guan; Robert R Redfield; Anthony L DeVico
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

2.  Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation.

Authors:  Elias David-Neto; Lilian Monteiro Pereira Araujo; Nairo Massakazu Sumita; Maria Elizabeth Mendes; Maria Cristina Ribeiro Castro; Cristiane Feres Alves; Erica Kakehashi; Paschoalina Romano; Elisa Midori Yagyu; Margaret Queiroga; William Carlos Nahas; Luiz Estevam Ianhez
Journal:  Pediatr Nephrol       Date:  2003-02-22       Impact factor: 3.714

Review 3.  Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant.

Authors:  Maria Grazia Revello; Giuseppe Gerna
Journal:  Clin Microbiol Rev       Date:  2002-10       Impact factor: 26.132

4.  Monoclonal IgG in MGUS and multiple myeloma targets infectious pathogens.

Authors:  Adrien Bosseboeuf; Delphine Feron; Anne Tallet; Cédric Rossi; Cathy Charlier; Laurent Garderet; Denis Caillot; Philippe Moreau; Marina Cardó-Vila; Renata Pasqualini; Wadih Arap; Alfreda Destea Nelson; Bridget S Wilson; Hélène Perreault; Eric Piver; Pierre Weigel; François Girodon; Jean Harb; Edith Bigot-Corbel; Sylvie Hermouet
Journal:  JCI Insight       Date:  2017-10-05

5.  Secondary monoclonal gammopathy of undetermined significance after allogeneic stem cell transplantation in multiple myeloma.

Authors:  Marian F Schmitz; Henny G Otten; Laurens E Franssen; Suzanne van Dorp; Theo Strooisma; Henk M Lokhorst; Niels W C J van de Donk
Journal:  Haematologica       Date:  2014-09-05       Impact factor: 9.941

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.